Who invested in AN2 Therapeutics

2 rounds we have observed, with the 5 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Raised 2 months ago

Funding summaryUpdated 26 Oct 2026

$80Mraised across 2 rounds since 2026, from 2 sources

$40MRound$40MGrant

Latest round: Grant, $40MSept 2026
Investors: 5

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

2027

$40MRound$40MGrant

First round: Round, $40M
Biggest round: $40M
Between rounds: 5 months

The rounds

Sept 2026
Grant$40M5 new
Source recorded
Mar 2026
Round$40M
No investor was named in the report.
Filed with the SEC (Form D); no report of this raise yetSEC filing: $40M sold, first sale Mar 2026

Founders and team

From AN2 Therapeutics's own website: 3 founders, 3 on the team.

Eric EasomCo-founder, President, CEO, and Chair

Maggie FitzPatrickFitzpatrick & Co, Founder & CEO

Joseph S. ZakrzewskiCo-founder and Director

Josh EizenChief Legal and Operating Officer
Lucy DayChief Financial Officer
Vince HernandezHead of Research

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Round2026Grant2026

RA Capital Management

Janus Henderson Investors

Vivo Capital

TCG

TCG Crossover

Everyone who backed them

RA Capital ManagementPrivate equity1round

Janus Henderson InvestorsPrivate equity1round

Vivo CapitalPrivate equity1round

TCGPrivate equity1round

TCG CrossoverVC firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 2 firms list AN2 Therapeutics as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.